FDA approved drug for the treatment of superficial basal cell carcinoma is ?
**Core Concept:** Superficial basal cell carcinoma (BCC) is a type of skin cancer that primarily affects the epidermis and dermis. It is typically treated using drugs that target the abnormal cell growth and promote apoptosis.
**Why the Correct Answer is Right:** Imiquimod is a topical immunomodulator that stimulates the immune system to recognize and attack cancerous cells, promoting apoptosis and tumor regression. It works by increasing the production of cytokines, interferons, and tumor necrosis factor-alpha, which leads to an enhanced immune response against cancerous cells.
**Why Each Wrong Option is Incorrect:**
A. 5-Fluorouracil (5-FU) is a chemotherapy drug that interferes with DNA and RNA synthesis, inhibiting cell division. However, it is not specifically targeted towards basal cell carcinoma and can have systemic side effects.
B. Calcipotriol is a vitamin D analog that is primarily used in the treatment of psoriasis, eczema, and other inflammatory skin conditions. It does not specifically target basal cell carcinoma and may exacerbate the condition in some cases.
C. Cryosurgery involves freezing the tumor with liquid nitrogen, causing immediate tissue damage and inflammation. Although it can be effective for small superficial BCCs, it may result in scarring and disfigurement, making it less suitable for larger or deeper lesions.
D. Photodynamic therapy (PDT) uses a photosensitizer (e.g., Levulan) applied to the skin and activated with a specific wavelength of light. It is effective for treating superficial BCCs but requires multiple sessions, can cause pain, and has limited penetration depth, making it less suitable for deeper or larger lesions.
**Clinical Pearl:** Imiquimod is an effective topical therapy for superficial basal cell carcinoma due to its targeted immunomodulatory effects and limited systemic side effects.
**Correct Answer:** Imiquimod (5%) cream is the correct answer as it is a targeted immunomodulator approved for the treatment of superficial basal cell carcinoma. It stimulates the immune system to recognize and eliminate cancerous cells, with limited systemic side effects when compared to other treatment modalities.